Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating
Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating Yahoo Finance
Covered in this story
What has happened since
- Abbott Laboratories is up 11.2% since this was published, 100 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Baird’s $121 target on $ABT is on the record and being tracked to Jul 2027 (12-month default), scored on the close that day.
Baird’s track record →Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 47 stories mentioning Abbott Laboratories, the earliest published 17 Apr 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.